Literature DB >> 16239528

Role of complement receptor type 2 and endogenous complement in the humoral immune response to conjugates of complement C3d and pneumococcal serotype 14 capsular polysaccharide.

Joyce K Mitsuyoshi1, Yong Hu, Samuel T Test.   

Abstract

Conjugation of the complement fragment C3d to both T-cell-dependent (TD) protein and T-cell-independent type 2 (TI-2) polysaccharide antigens enhances the humoral immune response in mice immunized with either type of antigen. However, the ability of C3d-protein conjugates to enhance the antibody response in mice deficient in complement receptor types 1 and 2 (CR1 and CR2) has raised questions about the role of C3d-CR2 interactions in the adjuvant effect of C3d. In this study, we examined the role of CR2 binding and endogenous complement activation in the antibody response to conjugates of C3d and serotype 14 pneumococcal capsular polysaccharide (PPS14). To block binding of PPS14-C3d conjugates to CR2, mice were immunized with a mixture of vaccine and (CR2)2-immunoglobulin G1 (IgG1). Mice receiving (CR2)2-IgG1 at the time of primary immunization had a marked reduction in the primary anti-PPS14 antibody response but an enhanced secondary anti-PPS14 response, suggesting that C3d-CR2 interactions are required for the primary response but can have negative effects on the memory response. Further, compared with mice receiving PPS14-C3d having a high C3d/PPS14 ratio, mice immunized with PPS14-C3d with low C3d/PPS14 ratios had an enhanced secondary antibody response. Treatment of mice with cobra venom factor to deplete complement had insignificant effects on the antibody response to PPS14-C3d. Experiments with CBA/N xid mice confirmed that PPS14-C3d conjugates retain the characteristics of TI-2 rather than TD antigens. Thus, the adjuvant effect of C3d conjugated to PPS14 requires C3d-CR2 interactions, does not require activation of endogenous complement, and is not mediated by TD carrier effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16239528      PMCID: PMC1273882          DOI: 10.1128/IAI.73.11.7311-7316.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

1.  Generation of recombinant human C3dg tetramers for the analysis of CD21 binding and function.

Authors:  S E Henson; D Smith; S A Boackle; V M Holers; D R Karp
Journal:  J Immunol Methods       Date:  2001-12-01       Impact factor: 2.303

2.  Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.

Authors:  T M Ross; Y Xu; T D Green; D C Montefiori; H L Robinson
Journal:  AIDS Res Hum Retroviruses       Date:  2001-06-10       Impact factor: 2.205

3.  Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses.

Authors:  Karen M Haas; Minoru Hasegawa; Douglas A Steeber; Jonathan C Poe; Mark D Zabel; Cheryl B Bock; David R Karp; David E Briles; John H Weis; Thomas F Tedder
Journal:  Immunity       Date:  2002-12       Impact factor: 31.745

4.  Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H.

Authors:  Jens Hellwage; T Sakari Jokiranta; Manuel A Friese; Tobias U Wolk; Eva Kampen; Peter F Zipfel; Seppo Meri
Journal:  J Immunol       Date:  2002-12-15       Impact factor: 5.422

5.  Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide.

Authors:  S T Test; J Mitsuyoshi; C C Connolly; A H Lucas
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

6.  C3d enhancement of neutralizing antibodies to measles hemagglutinin.

Authors:  T D Green; B R Newton; P A Rota; Y Xu; H L Robinson; T M Ross
Journal:  Vaccine       Date:  2001-10-12       Impact factor: 3.641

7.  Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin.

Authors:  Izumi Watanabe; Ted M Ross; Shin-ichi Tamura; Takeshi Ichinohe; Satoshi Ito; Hidehiro Takahashi; Hirofumi Sawa; Joe Chiba; Takeshi Kurata; Tetsutaro Sata; Hideki Hasegawa
Journal:  Vaccine       Date:  2003-11-07       Impact factor: 3.641

8.  Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins.

Authors:  Judy A Mitchell; Thomas D Green; Rick A Bright; Ted M Ross
Journal:  Vaccine       Date:  2003-02-14       Impact factor: 3.641

9.  Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.

Authors:  Thomas D Green; David C Montefiori; Ted M Ross
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1.

Authors:  Dominique Gatto; Thomas Pfister; Andrea Jegerlehner; Stephen W Martin; Manfred Kopf; Martin F Bachmann
Journal:  J Exp Med       Date:  2005-03-14       Impact factor: 14.307

View more
  5 in total

Review 1.  Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.

Authors:  Franklin R Toapanta; Ted M Ross
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  Fusion to chicken C3d enhances the immunogenicity of the M2 protein of avian influenza virus.

Authors:  Zhenhua Zhang; Yongqing Li; Shufang Xu; Fuyong Chen; Li Zhang; Beiyu Jiang; Xiaoling Chen
Journal:  Virol J       Date:  2010-05-09       Impact factor: 4.099

3.  C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2.

Authors:  Franklin R Toapanta; Dilhari R DeAlmeida; Matthew D Dunn; Ted M Ross
Journal:  Immunol Lett       Date:  2010-01-12       Impact factor: 3.685

4.  C3d adjuvant effects are mediated through the activation of C3d-specific autoreactive T cells.

Authors:  Anne S De Groot; Ted M Ross; Lauren Levitz; Timothy J Messitt; Ryan Tassone; Christine M Boyle; Amber J Vincelli; Leonard Moise; William Martin; Paul M Knopf
Journal:  Immunol Cell Biol       Date:  2014-11-11       Impact factor: 5.126

5.  Fixing a Hole: Preventing Pneumococcal Pneumonia by Vaccination.

Authors:  Ger T Rijkers
Journal:  Front Immunol       Date:  2016-09-13       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.